Rising sales of key drugs, lower one-time charges and reduced manufacturing costs helped to send profit at Pfizer up 50 percent in the second quarter.
The top U.S. drugmaker by sales beat Wall Street profit forecasts, tweaked its own forecast for the year, and predicted numerous lucrative drugs will be approved over the next half-decade.
Still, cheaper generic competition continues to gnaw away at Pfizer’s revenue, which fell short of analyst expectations.
The Viagra maker reported quarterly profit of $3.07 billion, or 51 cents per share on Tuesday. That’s up from $2.05 billion, or 33 cents per share, a year earlier.
Adjusted income of 67 cents per share beat by two cents the average of analyst estimates, according to a poll by Zacks Investment Research.
The New York drugmaker posted revenue of $12.9 billion, just missing forecasts for $13.02 billion.
Top sellers including Lyrica, new breast cancer drug Ibrance and blood thinner Eliquis all produced higher sales, helping lift revenue from Pfizer’s patented-protected drugs by 8 percent, to $7.67 billion. Pfizer’s essential health segment, which sells older products that are mostly off patent, had sales dip 5 percent to $2.71 billion.
“We have a strong pipeline with a steady flow of scientific innovation coming from all of our key therapeutic areas,” CEO Ian Read said in a company release. “Over the next five years, we project the potential for approximately 25 to 30 approvals of which up to 15 have the potential to be blockbusters,” meaning their annual sales would top $1 billion.
Sales at Pfizer’s consumer health business edged up 1 percent, to $846 million.
Pfizer now expects full-year earnings in the range of $2.54 to $2.60 per share, raising just the lower end from the company’s May forecast by 4 cents. The company maintained a 2017 revenue forecast of between $52 billion and $54 billion.
Pfizer shares, up 2 percent since the beginning of the year, rose about 1 percent before the opening bell.
_____
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
___
Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma
